Advertisement
Screener

EXOZYMES INC. (EXOZ) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

EXOZYMES INC. Operating Cash Flow

EXOZYMES INC. (EXOZ) reported Operating Cash Flow of -$3.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13

  • EXOZYMES INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.64M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.52M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.97M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.86M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for fiscal 2025 was -$6.50M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for fiscal 2024 was -$8.51M.
  • EXOZYMES INC. net cash provided by (used in) operating activities for fiscal 2023 was -$1.18M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$1.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$3.16M
10-Q · filed 2026-08-13
-$5.14M
derived: sum of 3 quarters · filed 2026-08-13
-$7.00M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$1.52M
10-Q · filed 2026-05-14
-$3.50M
derived: sum of 2 quarters · filed 2026-05-14
-$5.35M
derived: sum of 3 quarters · filed 2026-05-14
-$6.89M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$1.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$3.83M
derived: sum of 2 quarters · filed 2026-03-30
-$5.37M
derived: sum of 3 quarters · filed 2026-08-13
-$6.50M
10-K · filed 2026-03-30
2025-09-30-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$3.39M
derived: sum of 2 quarters · filed 2026-08-13
-$4.53M
10-Q · filed 2025-11-13
-$10.24M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$1.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$2.67M
10-Q · filed 2026-08-13
-$8.38M
derived: sum of 3 quarters · filed 2026-08-13
-$8.92M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$1.13M
10-Q · filed 2026-05-14
-$6.84M
derived: sum of 2 quarters · filed 2026-05-14
-$7.38M
derived: sum of 3 quarters · filed 2026-05-14
-$9.92M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$5.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$6.25M
derived: sum of 2 quarters · filed 2026-03-30
-$8.79M
derived: sum of 3 quarters · filed 2026-03-30
-$8.51M
10-K · filed 2026-03-30
2024-09-30-$541.52K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$3.08M
derived: sum of 2 quarters · filed 2025-11-13
-$2.80M
10-Q · filed 2025-11-13
-$3.58M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$2.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$2.26M
10-Q · filed 2025-08-12
-$3.04M
derived: sum of 3 quarters · filed 2025-08-12
2024-03-31$281.20K
10-Q · filed 2025-05-12
-$502.08K
derived: sum of 2 quarters · filed 2025-05-12
2023-12-31-$783.28K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$1.18M
10-K · filed 2025-03-31
2023-09-30-$397.59K
10-Q · filed 2024-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
BioStem Technologies, Inc. (BSEM)United States$0.069B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02